ExpreS2ion CEO interviewed, CFO provides update at life science investor conference, Analysguiden publishes research report

Hørsholm, Denmark, 27 November 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that ExpreS2ion CEO Bent Frandsen participated in a Finwire interview, CFO Keith Alexander participated in the Økonomisk Ugebrev Life Science Investor Conference on 22 November, and Analysguiden has published a research report on ExpreS2ion in November.

An interview with CEO Bent Frandsen, hosted by Finwire, and a presentation by CFO Keith Alexander at the Økonomisk Ugebrev Life Science Investor Conference on 22 November 2023, can both be found on the presentations page of the ExpreS²ion investor website.

The Analysguiden report dives deeper into the Company’s strategic changes and comments on a potential dividend payment related to milestones from the ABNCoV2 COVID-19 vaccine, the “post-covid” strategy, especially as it relates to the ES2B-C001 breast cancer vaccine asset, updates to the malaria programs and valuation, including an analysis of ExpreS²ion’s holding in AdaptVac ApS. Analysguiden revised its price target to SEK 2.20 per share. The research report is available on the Analyst Reports page of ExpreS²ion’s investor website.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB